Myeloid cells are the most abundant nucleated hematopoietic cells in the body, consisting of a range of cell types with diverse functions. They include monocytes, macrophages, DCs and granulocytes, and make up a critical arm of the immune system.
At Aquila, our immunology experts can help you understand if your compound or biologic affects the phenotype or function of myeloid cells, in an isolated cell type setting, or in a co-culture environment, ensuring the most appropriate level of complexity for you immunology discovery program.
Our monocyte and macrophage monocultures are ideal for pre-clinical optimisation (e.g. determining dose response) without expensive animal testing. Our M1 macrophage assays are designed for studying compounds that inhibit pro-inflammatory responses in autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. M2 macrophage assays are best suited for drug candidates designed to reverse suppression of the immune system by the tumour microenvironment.
Dendritic cells, especially inflammatory DCs, arise from circulating monocytes. We can help you understand if your drug candidate impacts this differentiation process. Alternatively, we can support your investigations into your compound effect on the maturation of DCs.
For clients beginning in vivo studies or clinical trials, we offer functional assays for confirming drug effectiveness. For more information on our customisable Myeloid Assays click here.
Our experienced staff are specialists in specific immune cells and work closely with you to build a stronger data package and speed up your route to clinic.
Please get in touch to learn more about our myeloid cell related services.